Recent resurgence of mumps in the United States.

BACKGROUND The widespread use of a second dose of mumps vaccine among U.S. schoolchildren beginning in 1990 was followed by historically low reports of mumps cases. A 2010 elimination goal was established, but in 2006 the largest mumps outbreak in two decades occurred in the United States. METHODS We examined national data on mumps cases reported during 2006, detailed case data from the most highly affected states, and vaccination-coverage data from three nationwide surveys. RESULTS A total of 6584 cases of mumps were reported in 2006, with 76% occurring between March and May. There were 85 hospitalizations, but no deaths were reported; 85% of patients lived in eight contiguous midwestern states. The national incidence of mumps was 2.2 per 100,000, with the highest incidence among persons 18 to 24 years of age (an incidence 3.7 times that of all other age groups combined). In a subgroup analysis, 83% of these patients reported current college attendance. Among patients in eight highly affected states with known vaccination status, 63% overall and 84% between the ages of 18 and 24 years had received two doses of mumps vaccine. For the 12 years preceding the outbreak, national coverage of one-dose mumps vaccination among preschoolers was 89% or more nationwide and 86% or more in highly affected states. In 2006, the national two-dose coverage among adolescents was 87%, the highest in U.S. history. CONCLUSIONS Despite a high coverage rate with two doses of mumps-containing vaccine, a large mumps outbreak occurred, characterized by two-dose vaccine failure, particularly among midwestern college-age adults who probably received the second dose as schoolchildren. A more effective mumps vaccine or changes in vaccine policy may be needed to avert future outbreaks and achieve the elimination of mumps.

[1]  M. Kolasa,et al.  Progress toward implementation of a second-dose measles immunization requirement for all schoolchildren in the United States. , 2004, The Journal of infectious diseases.

[2]  I. Julkunen,et al.  Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up. , 1995, Vaccine.

[3]  D. L. Wilson,et al.  Mumps outbreak in a highly vaccinated school population. Evidence for large-scale vaccination failure. , 1995, Archives of pediatrics & adolescent medicine.

[4]  W. Schaffner,et al.  A large outbreak of mumps in the postvaccine era. , 1988, The Journal of infectious diseases.

[5]  Richard Harling,et al.  The effectiveness of the mumps component of the MMR vaccine: a case control study. , 2005, Vaccine.

[6]  A. Galazka,et al.  Mumps and mumps vaccine: A global review , 1999, Bulletin of the World Health Organization.

[7]  R. May,et al.  Infectious Diseases of Humans: Dynamics and Control , 1991, Annals of Internal Medicine.

[8]  Laura H. Kahn,et al.  Mumps outbreak in a highly vaccinated population. , 1991, The Journal of pediatrics.

[9]  J. Schaffzin,et al.  Effectiveness of Previous Mumps Vaccination During a Summer Camp Outbreak , 2007, Pediatrics.

[10]  M. Lindegren,et al.  Mumps surveillance--United States, 1988-1993. , 1995, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[11]  A. Curns,et al.  Mumps vaccine performance among university students during a mumps outbreak. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  C. A. Werner Mumps orchitis and testicular atrophy; occurrence. , 1950, Annals of internal medicine.

[13]  P. Quinlisk,et al.  Exposure to mumps during air travel--United States, April 2006. , 2006, MMWR. Morbidity and mortality weekly report.

[14]  R. Parker,et al.  Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine-induced immunity. , 1994, The Journal of infectious diseases.

[15]  G. Palacios,et al.  Sensitivity and specificity of immunoglobulin G titer for the diagnosis of mumps virus in infected patients depending on vaccination status , 2006, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[16]  N. Andrews,et al.  Vaccine Effectiveness Estimates, 2004–2005 Mumps Outbreak, England , 2007, Emerging infectious diseases.

[17]  W. Bellini,et al.  Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak. , 2008, The Journal of infectious diseases.

[18]  M. Burns,et al.  Case-Control Study , 2020, Definitions.

[19]  Mumps epidemic--United kingdom, 2004-2005. , 2006, MMWR. Morbidity and mortality weekly report.

[20]  Hadler Sc,et al.  Mumps surveillance--United States, 1988-1993. , 1995 .

[21]  C. Orvell,et al.  Mumps virus neutralizing antibodies do not protect against reinfection with a heterologous mumps virus genotype. , 2001, Vaccine.

[22]  T. Ezzati-Rice,et al.  Forty years and four surveys: how does our measuring measure up? , 2001, American journal of preventive medicine.

[23]  M. Ogilvie,et al.  Real-time PCR for mumps diagnosis on clinical specimens--comparison with results of conventional methods of virus detection and nested PCR. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[24]  P. Quinlisk,et al.  Update: multistate outbreak of mumps--United States, January 1-May 2, 2006. , 2006, MMWR. Morbidity and mortality weekly report.

[25]  A. Kirn,et al.  Rapid diagnosis of acute mumps infection by a direct immunoglobulin M antibody capture enzyme immunoassay with labeled antigen , 1985, Journal of clinical microbiology.

[26]  Roy M. Anderson,et al.  Vaccination and herd immunity to infectious diseases , 1985, Nature.

[27]  P. Litton,et al.  Genetic diversity of mumps virus in oral fluid specimens: application to mumps epidemiological study. , 2004, The Journal of infectious diseases.